DMD steals the health of thousands of young boys. Atossa Therapeutics is researching a new approach to treatment that may offer hope.
Families dealing with Duchenne Muscular Dystrophy (DMD) experience the heartbreak of watching a child suffer from a debilitating, incurable disease.
A different approach
DMD occurs due to a genetic mutation primarily affecting boys, inhibiting production of a protein called dystrophin, which maintains and repairs muscle cells. This results in a steady decline in muscle function and shortened life expectancy.
Atossa Therapeutics is evaluating whether impacting a protein called utrophin, which is functionally similar to dystrophin, may replace the shortened or missing dystrophin and could result in impactful treatment for DMD. This approach may also benefit female carriers of the DMD mutation, who often experience skeletal muscle loss later in life.
Early research leading to future clinical trials is encouraging, offering something families desperately need: Hope.
